Richard G. Langley

Research interests

Publications

• Bimekizumab versus Secukinumab in Plaque Psoriasis

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2102383

• Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00125-2

• Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)31773-8

• Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial

  British Journal of Dermatology · 2017 · https://doi.org/10.1111/bjd.15750

• Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1512711

• A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

  British Journal of Dermatology · 2016 · https://doi.org/10.1111/bjd.14493

• Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1503824

• Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

  Journal of the American Academy of Dermatology · 2015 · https://doi.org/10.1016/j.jaad.2015.03.049

• Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

  British Journal of Dermatology · 2015 · https://doi.org/10.1111/bjd.14018

• Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1314258

• Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

  Journal of the American Academy of Dermatology · 2014 · https://doi.org/10.1016/j.jaad.2013.12.018

• Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

  British Journal of Dermatology · 2012 · https://doi.org/10.1111/j.1365-2133.2012.11168.x

• Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

  British Journal of Dermatology · 2012 · https://doi.org/10.1111/bjd.12110

• Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events

  JAMA · 2011 · https://doi.org/10.1001/jama.2011.1211

• Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmoa066886

• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

  The Lancet · 2008 · https://doi.org/10.1016/s0140-6736(08)60726-6

• Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

  Journal of the American Academy of Dermatology · 2007 · https://doi.org/10.1016/j.jaad.2007.09.010

• Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

  British Journal of Dermatology · 2007 · https://doi.org/10.1111/j.1365-2133.2007.08315.x

• A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis

  New England Journal of Medicine · 2007 · https://doi.org/10.1056/nejmoa062382

• Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis

  Archives of Dermatology · 2007 · https://doi.org/10.1001/archderm.143.6.719

• Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

  Journal of the American Academy of Dermatology · 2006 · https://doi.org/10.1016/j.jaad.2006.05.027

• Psoriasis: epidemiology, clinical features, and quality of life

  Annals of the Rheumatic Diseases · 2005 · https://doi.org/10.1136/ard.2004.033217

• Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment

  Journal of the American Academy of Dermatology · 2004 · https://doi.org/10.1016/j.jaad.2004.04.012

• An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis

  Archives of Dermatology · 2003 · https://doi.org/10.1001/archderm.139.6.719

• Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents

  Journal of the American Academy of Dermatology · 2002 · https://doi.org/10.1067/mjd.2002.122187

Current projects

No projects listed.